公开(公告)号：US08735402B2

公开(公告)日：2014-05-27

申请号：US13532305

申请日：2012-06-25

Applicant: Dieter Kadereit ,  Matthias Schaefer ,  Stephanie Hachtel ,  Thomas Huebschle ,  Katrin Hiss ,  Silke Haag-Diergarten

Inventor： Dieter Kadereit ,  Matthias Schaefer ,  Stephanie Hachtel ,  Thomas Huebschle ,  Katrin Hiss ,  Silke Haag-Diergarten

IPC: A01N43/90 ,  A61K31/519 ,  C07D471/00 ,  C07D487/00 ,  C07D491/00

CPC classification number: C07D498/04

Abstract: The present invention relates to cycloalkyloxycarboxylic acid derivatives of the formula I in which A, R1, R2a, R2b, R2c, R3 and X are as defined in the claims. The compounds of the formula I are suitable, for example, for wound healing.

Abstract translation: 本发明涉及式I的环烷氧基羧酸衍生物，其中A，R1，R2a，R2b，R2c，R3和X如权利要求中所定义。 式I的化合物适用于例如伤口愈合。

公开(公告)号：US08618304B2

公开(公告)日：2013-12-31

申请号：US13461264

申请日：2012-05-01

Applicant: Josef Pernerstorfer ,  Heinz-Werner Kleemann ,  Matthias Schaefer ,  Alena Safarova ,  Marcel Patek

Inventor： Josef Pernerstorfer ,  Heinz-Werner Kleemann ,  Matthias Schaefer ,  Alena Safarova ,  Marcel Patek

IPC: C07D401/00 ,  A61K31/44

CPC classification number: C07C235/54 ,  C07C231/00 ,  C07C231/02 ,  C07C235/42 ,  C07C235/84 ,  C07C255/50 ,  C07C255/54 ,  C07C255/57 ,  C07C307/10 ,  C07C317/46 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2601/18 ,  C07C2602/22 ,  C07C2602/50 ,  C07D213/16 ,  C07D213/64 ,  C07D213/69 ,  C07D213/81 ,  C07D213/82 ,  C07D231/12 ,  C07D231/18 ,  C07D305/04 ,  C07D305/06 ,  C07D305/08 ,  C07D309/04 ,  C07D309/08 ,  C07D309/14 ,  C07D313/04 ,  C07D317/06 ,  C07D317/68 ,  C07D317/72 ,  C07D333/16 ,  C07D333/32 ,  C07D335/02 ,  C07D335/14 ,  C07D335/18 ,  C07D493/10

Abstract: The present invention relates to compounds of the formula I, wherein A, Y, Z, R20 to R22 and R50 have the meanings indicated in the claims, which are pharmaceutically active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA1 receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.

Abstract translation: 本发明涉及式I化合物，其中A，Y，Z，R 20至R 22和R 50具有权利要求中所述的含义，其为药学活性化合物。 具体来说，它们是由溶血磷脂酸（LPA）激活的内皮分化基因受体2（Edg-2，EDG2）的抑制剂，也被称为LPA1受体，可用于治疗动脉粥样硬化，心肌的疾病 梗死和心力衰竭。 本发明还涉及制备式I化合物的方法，其用途和包含它们的药物组合物。

公开(公告)号：US20130256434A1

公开(公告)日：2013-10-03

申请号：US13902396

申请日：2013-05-24

Applicant: Matthias Schaefer ,  Michael Lechner ,  Uwe Neumann ,  Dimitrios Makrakis ,  Udo Enderle ,  Gerhard Kolb ,  Stefan Mende ,  Klaus Ott ,  Horst Pausch ,  Michael Rappl ,  Peter Schertenleib ,  Michael Schmidt ,  Peter Stich ,  Lars Weiland

Inventor： Matthias Schaefer ,  Michael Lechner ,  Uwe Neumann ,  Dimitrios Makrakis ,  Udo Enderle ,  Gerhard Kolb ,  Stefan Mende ,  Klaus Ott ,  Horst Pausch ,  Michael Rappl ,  Peter Schertenleib ,  Michael Schmidt ,  Peter Stich ,  Lars Weiland

IPC: B02C17/20

CPC classification number: B02C17/205 ,  B02C17/161

Abstract: A method for the introduction of auxiliary grinding bodies into an agitator ball mill and for the removal of auxiliary grinding bodies from an agitator ball mill. The auxiliary grinding bodies are transported into the agitator ball mill and out of the latter via a closed circuit by means of a hydraulic conveying medium.

Abstract translation: 一种用于将辅助研磨体引入搅拌器球磨机中并用于从搅拌器球磨机去除辅助研磨体的方法。 辅助研磨体通过液压输送介质通过闭合回路输送到搅拌器球磨机中并从其中流出。

公开(公告)号：US20130072501A1

公开(公告)日：2013-03-21

申请号：US13521825

申请日：2011-01-14

Applicant: Dieter Kadereit ,  Matthias Schaefer ,  Stephanie Hachtel ,  Axel Dietrich ,  Thomas Huebschle ,  Katrin Hiss

Inventor： Dieter Kadereit ,  Matthias Schaefer ,  Stephanie Hachtel ,  Axel Dietrich ,  Thomas Huebschle ,  Katrin Hiss

IPC: C07D498/04 ,  A61P17/02 ,  A61K31/519

CPC classification number: C07D498/04 ,  A61K31/519 ,  C07D498/22

Abstract: The invention relates to oxazolopyrimidine compounds of formula I, where A, R1 and R2 are defined as stated in the claims. The compounds of formula I are suitable, for example, for wound healing.

Abstract translation: 本发明涉及式I的恶唑并嘧啶化合物，其中A，R 1和R 2如权利要求中所定义。 式I化合物适用于例如伤口愈合。

公开(公告)号：US20120253001A1

公开(公告)日：2012-10-04

申请号：US13517389

申请日：2010-11-15

Applicant: Bindushree Radhakrishnan ,  Dwight D. Latham ,  Laura A. Grier ,  William A. Koonce ,  Matthias Schaefer ,  Paul D. Ries

Inventor： Bindushree Radhakrishnan ,  Dwight D. Latham ,  Laura A. Grier ,  William A. Koonce ,  Matthias Schaefer ,  Paul D. Ries

IPC: C08G18/32 ,  C08G18/34

CPC classification number: C09K3/1021 ,  C08G18/10 ,  C08G18/36 ,  C08G18/4288 ,  C08G18/4891 ,  C08G18/6674 ,  C08G2190/00 ,  C08K5/10 ,  C08G18/664 ,  C08L75/04

Abstract: Insulated glass units are sealed with polyurethane made using a natural oil-based polyol (NOBP). In one embodiment the NOBP is made using a monol-rich monomer containing high levels of mono-hydroxy functional fatty acid methyl esters. Insulated glass sealants based on these compounds provide enhanced resistance to UV and oxidative degradation as compared to conventional products while still providing the required barrier and mechanical properties.

Abstract translation: 绝缘玻璃单元使用天然油基多元醇（NOBP）制成的聚氨酯密封。 在一个实施方案中，使用含有高含量单羟基官能脂肪酸甲酯的单醇富含单体制备NOBP。 与常规产品相比，基于这些化合物的绝缘玻璃密封剂提供了对UV和氧化降解的增强的抗性，同时仍然提供所需的屏障和机械性能。

公开(公告)号：US07104770B2

公开(公告)日：2006-09-12

申请号：US10665554

申请日：2003-09-22

Applicant: Helmut Bauer ,  Christoph Boehnisch ,  Reinhard Denk ,  Matthias Gradl ,  Michael Groth ,  Guido Gutmann ,  Guenther Hantschk ,  Siegfried Jarzina ,  Franz Kneidl ,  Johann Kreidl ,  Robert Kurz ,  Franz Lachenwitzer ,  Uwe Neumann ,  Hansjuergen Linde ,  Thomas Ribbe ,  Michael Robby ,  Karl-Heinz Rosner ,  Matthias Schaefer ,  Thomas Streubel ,  Alfred Thumser

Inventor： Helmut Bauer ,  Christoph Boehnisch ,  Reinhard Denk ,  Matthias Gradl ,  Michael Groth ,  Guido Gutmann ,  Guenther Hantschk ,  Siegfried Jarzina ,  Franz Kneidl ,  Johann Kreidl ,  Robert Kurz ,  Franz Lachenwitzer ,  Uwe Neumann ,  Hansjuergen Linde ,  Thomas Ribbe ,  Michael Robby ,  Karl-Heinz Rosner ,  Matthias Schaefer ,  Thomas Streubel ,  Alfred Thumser

IPC: F03C2/00 ,  F04C18/00

CPC classification number: F04C2/1075

Abstract: The present invention relates to the arrangement of a stator and a spare stator. In order to avoid a permanent correction in the length of the driving shaft, the spare stator is connected to the instantaneously operated stator or is configured in a single piece. Upon occurrence of a defined amount of wear, this stator combination is merely reversed through 180° relative to the longitudinal axis or an intermediate tube is inserted so that the spare stator arrives in the rotor region.

Abstract translation: 本发明涉及定子和备用定子的布置。 为了避免在驱动轴的长度上的永久校正，备用定子连接到瞬时操作的定子或者被配置成单件。 当发生规定的磨损量时，该定子组合仅相对于纵向轴线反转180°，或插入中间管，使得备用定子到达转子区域。

公开(公告)号：US20050100468A1

公开(公告)日：2005-05-12

申请号：US10665554

申请日：2003-09-22

Applicant: Helmut Bauer ,  Christoph Boehnisch ,  Reinhard Denk ,  Matthias Gradl ,  Michael Groth ,  Guido Gutmann ,  Guenther Hantschk ,  Siegfried Jarzina ,  Franz Kneidl ,  Johann Kreidl ,  Robert Kurz ,  Franz Lachenwitzer ,  Uwe Neumann ,  Hansjuergen Linde ,  Thomas Ribbe ,  Michael Robby ,  Karl-Heinz Rosner ,  Matthias Schaefer ,  Thomas Streubel ,  Alfred Thumser

Inventor： Helmut Bauer ,  Christoph Boehnisch ,  Reinhard Denk ,  Matthias Gradl ,  Michael Groth ,  Guido Gutmann ,  Guenther Hantschk ,  Siegfried Jarzina ,  Franz Kneidl ,  Johann Kreidl ,  Robert Kurz ,  Franz Lachenwitzer ,  Uwe Neumann ,  Hansjuergen Linde ,  Thomas Ribbe ,  Michael Robby ,  Karl-Heinz Rosner ,  Matthias Schaefer ,  Thomas Streubel ,  Alfred Thumser

IPC: F04C2/107 ,  F01C1/10

CPC classification number: F04C2/1075

Abstract: The present invention relates to the arrangement of a stator and a spare stator. In order to avoid a permanent correction in the length of the driving shaft, the spare stator is connected to the instantaneously operated stator or is configured in a single piece. Upon occurrence of a defined amount of wear, this stator combination is merely reversed through 180° relative to the longitudinal axis or an intermediate tube is inserted so that the spare stator arrives in the rotor region.

Abstract translation: 本发明涉及定子和备用定子的布置。 为了避免在驱动轴的长度上的永久校正，备用定子连接到瞬时操作的定子或者被配置成单件。 当发生规定的磨损量时，该定子组合仅相对于纵向轴线反转180°，或插入中间管，使得备用定子到达转子区域。

公开(公告)号：US08846690B2

公开(公告)日：2014-09-30

申请号：US13521828

申请日：2011-01-12

Applicant: Dieter Kadereit ,  Matthias Schaefer ,  Stephanie Hachtel ,  Axel Dietrich ,  Thomas Huebschle ,  Katrin Hiss

Inventor： Dieter Kadereit ,  Matthias Schaefer ,  Stephanie Hachtel ,  Axel Dietrich ,  Thomas Huebschle ,  Katrin Hiss

IPC: A01N43/90 ,  A61K31/519 ,  C07D239/00 ,  C07D498/04

CPC classification number: C07D498/04

Abstract: Heterocyclic carboxylic acid derivatives comprising a 2,5-substituted oxazolopyrimidine ring as Edg-1 receptor agonistsThe present invention relates to oxazolopyrimidine compounds of the formula I, in which A, R1, R2, R3, X and Y are defined as indicated in the claims. The compounds of the formula I modulate the activity of the Edg-1 receptor and in particular are agonists of this receptor, and are useful for the treatment of diseases such as atherosclerosis, heart failure or peripheral arterial occlusive disease, for example. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

Abstract translation: 包含2,5-取代的恶唑啉嘧啶环作为Edg-1受体激动剂的杂环羧酸衍生物本发明涉及式I的恶唑并嘧啶化合物，其中A，R 1，R 2，R 3，X和Y如 声称。 式I的化合物调节Edg-1受体的活性，特别是该受体的激动剂，并且可用于例如治疗动脉粥样硬化，心力衰竭或外周动脉闭塞性疾病等疾病。 本发明还涉及制备式I化合物的方法，其用途，特别是作为药物中的活性成分，以及包含它们的药物组合物。

公开(公告)号：US08785439B2

公开(公告)日：2014-07-22

申请号：US13521823

申请日：2011-01-12

Applicant: Dieter Kadereit ,  Matthias Schaefer ,  Stephanie Hachtel ,  Axel Dietrich ,  Thomas Huebschle ,  Andreas Gille ,  Katrin Hiss

Inventor： Dieter Kadereit ,  Matthias Schaefer ,  Stephanie Hachtel ,  Axel Dietrich ,  Thomas Huebschle ,  Andreas Gille ,  Katrin Hiss

IPC: C07D401/00 ,  C07D498/04

CPC classification number: C07D498/04

Abstract: The invention relates to oxazolopyrimidine compounds of formula (I), where A, R1, R2 and R3 are defined as stated in the claims. The compounds of formula (I) are suitable, for example, for wound healing.

Abstract translation: 本发明涉及式（I）的恶唑并嘧啶化合物，其中A，R 1，R 2和R 3如权利要求中所定义。 式（I）化合物适用于例如伤口愈合。

公开(公告)号：US08735387B2

公开(公告)日：2014-05-27

申请号：US13003125

申请日：2009-07-02

Applicant: Dieter Kadereit ,  Matthias Schaefer ,  Werngard Czechtizky

Inventor： Dieter Kadereit ,  Matthias Schaefer ,  Werngard Czechtizky

IPC: C07D498/04 ,  A61K31/519 ,  A61P9/00 ,  A61P9/10 ,  A61P29/00 ,  A61P25/28 ,  A61P35/00

CPC classification number: C07D498/04 ,  C07D519/00

Abstract: The present invention relates to oxazolopyrimidine compounds of the formula I in which A, R1, R2 and R3 are defined as indicated in the claims. The compounds of the formula I modulate the activity of the Edg-1 receptor and in particular are agonists of this receptor, and are useful for the treatment of diseases such as atherosclerosis, heart failure or peripheral arterial occlusive disease, for example. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

Abstract translation: 本发明涉及式I的恶唑并嘧啶化合物，其中A，R 1，R 2和R 3如权利要求中所定义。 式I的化合物调节Edg-1受体的活性，特别是该受体的激动剂，并且可用于例如治疗动脉粥样硬化，心力衰竭或外周动脉闭塞性疾病等疾病。 本发明还涉及制备式I化合物的方法，其用途，特别是作为药物中的活性成分，以及包含它们的药物组合物。